Controlling Shareholder Establishes New $24.9M Stock Sale Plan
PAHC sits 48% above its 52-week low of $22.51.
Summary
A controlling shareholder has initiated a new Rule 10b5-1 plan to sell up to $24.9 million in stock, adding to recent sales and indicating ongoing insider distribution.
Key Events · Ownership and Investor Activity · PAHC
-
New 10b5-1 Sales Plan Established
Jack C. Bendheim's entity, BFI Co., LLC, adopted a new Rule 10b5-1 plan to sell up to 750,000 shares of Class A Common Stock through March 2027, with sales commencing in September 2026.
-
Significant Future Selling Pressure
The shares covered by the new plan are valued at approximately $24.9 million, representing about 1.85% of the company's current market capitalization, indicating a substantial future overhang.
-
Ongoing Insider Sales
The filing also disclosed additional sales of 39,728 shares between April 28 and May 7, 2026, totaling approximately $2.56 million, continuing a trend of distribution by the controlling shareholder.
-
Controlling Stake Maintained
Despite the sales and future plan, Jack C. Bendheim and BFI Co., LLC will continue to beneficially own a controlling stake of approximately 48.2% of the company's common stock.
Analysis · PAHC · Life Sciences
Jack C. Bendheim, a controlling shareholder, has established a new Rule 10b5-1 plan to sell up to 750,000 shares, valued at approximately $24.9 million based on current prices. This plan, set to begin in September 2026, signals a significant future selling pressure from a major insider. The filing also reports additional sales of approximately $2.56 million since the last amendment, continuing a pattern of distribution by the insider.
At the time of this filing, PAHC was trading at $33.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $22.51 to $60.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.